Provided by Tiger Trade Technology Pte. Ltd.

uniQure NV

47.46
-0.9100-1.88%
Post-market: 47.460.00000.00%16:15 EDT
Volume:920.82K
Turnover:43.56M
Market Cap:3.29B
PE:-11.75
High:48.04
Open:48.00
Low:46.34
Close:48.37
52wk High:71.50
52wk Low:8.73
Shares:69.37M
Float Shares:57.53M
Volume Ratio:1.02
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0399
EPS(LYR):-3.4602
ROE:-157.61%
ROA:-15.72%
PB:10.16
PE(LYR):-13.72

Loading ...

uniQure Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Jun 19

UniQure's Approval Path Looks Stronger After US FDA Feedback, RBC Capital Markets Says

MT Newswires Live
·
Jun 18

uniQure price target raised to $70 from $36 at Leerink

TIPRANKS
·
Jun 18

Analysts Are Bullish on These Healthcare Stocks: uniQure (QURE), Biohaven Ltd. (BHVN)

TIPRANKS
·
Jun 18

uniQure upgraded to Overweight from Equal Weight at Barclays

TIPRANKS
·
Jun 18

RBC Raises Price Target on uniQure to $65 From $35, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jun 18

Uniqure Nv : Leerink Partners Raises Target Price to $70 From $36

THOMSON REUTERS
·
Jun 18

TD Cowen Sticks to Their Buy Rating for uniQure (QURE)

TIPRANKS
·
Jun 18

uniQure director Madhavan Balachandran disposes of USD 278,500 in common shares

Reuters
·
Jun 18

Under the Radar: uniQure Shares Surge After FDA's Reversal on Gene Therapy -- WSJ

Dow Jones
·
Jun 18

Top Midday Gainers

MT Newswires Live
·
Jun 18

uniQure upgraded to Overweight from Neutral at Cantor Fitzgerald

TIPRANKS
·
Jun 17

BUZZ-U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron

Reuters
·
Jun 17

UniQure Stock (QURE) Rockets on an FDA Update

TIPRANKS
·
Jun 17

This Biotech Stock Is Surging 66% on Surprise Good News From FDA -- Barrons.com

Dow Jones
·
Jun 17

Uniqure Nv : Van Lanschot Kempen Raises Target Price to $60 From $27

THOMSON REUTERS
·
Jun 17

uniQure AMT-130 update ‘materially positive,’ says H.C. Wainwright

TIPRANKS
·
Jun 17

UniQure to Seek FDA Approval to Market Huntington's Disease Drug

Dow Jones
·
Jun 17

uniQure announces plan for BLA submission for AMT-130

TIPRANKS
·
Jun 17

uniQure says FDA accepts Phase I/II data as basis for AMT-130 accelerated approval BLA

Reuters
·
Jun 17